Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi (EGEPO) Fair Value & Analysis
Healthcare · TR · Market cap 9.4B TRY
Fair value as of: Aug 7, 2026
From 15 valuation models · updated yesterday
Share price +2.7% over the past month.
Below-average quality, and screening another 36% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (15.26 TRY). The favourable scenario is already priced in.
- Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (8.11 TRY to 15.26 TRY) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 7, 2026.
How to read this chart
59‑month range 1.28 TRY – 19.92 TRY · fair‑value band 8.11 TRY – 15.26 TRY · the 18.74 TRY price screens above the 11.92 TRY fair value. Dashed = 300-day average. As of Aug 7, 2026.
Analysis
Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi (EGEPO) currently trades at 18.74 TRY, while our model-based Fair Value estimate is 11.92 TRY, implying the stock looks roughly 36.4% overvalued today. We read business quality at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi generated revenue of 1.5B TRY at a net margin of -3.7%. Revenue grew 28.1% year over year. It earns a return on equity of -3.0%. Net debt stands at 14.3M TRY. Fundamentals as of Aug 7, 2026
Our scenario range runs from 8.11 TRY (bear case) to 15.26 TRY (bull case); at 18.74 TRY, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 9% below its 52-week high and 180% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -36%, EGEPO screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Asset-Based (127.15 TRY) versus Multiples (5.46 TRY). Highest evidence: ROIC Compounder (72).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 37 · Market factors (momentum, volatility) 82
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi provides outpatient and inpatient examination, diagnosis, and treatment services to patients in Turkey.
Full company description
Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi provides outpatient and inpatient examination, diagnosis, and treatment services to patients in Turkey. The company constructs, renovates, establishes, purchases, and operates diagnostic and treatment facilities, laboratories, blood banks, rehabilitation centers, and other health-related institutions; and provides all health services, including preventive medicine. It operates hospitals for emergency and emergency medical services, anesthesiology and reanimation, nutrition and dietetics, neurosurgery, pediatrics, dermatology, infectious diseases and clinical microbiology, aesthetics, plastic and reconstructive surgery, physical therapy and rehabilitation, gastroenterology, general surgery, interventional radiology, pulmonology, ophthalmology, internal medicine, obstetrics and gynecology, cardiovascular surgery, clinical biochemistry, neurology, orthopedics and traumatology, palliative care, psychiatry, psychology, radiology, urology, intensive care adult, intensive care coronary, intensive care cardiovascular surgery, and intensive care neonatal, as well as various otolaryngology diseases, such as ear, nose, and throat. The company was incorporated in 2003 and is based in Izmir, Turkey.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi reported revenue of 1.3B TRY in FY2025 versus 170M TRY in FY2021, a compound +67.8%/yr. Reported net income was 2.7M TRY in FY2025, compounding −37.5%/yr from FY2021.
EGEPO screens 36% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 262 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi (EGEPO) overvalued or undervalued?
What is the fair value of EGEPO?
What is the quality score of EGEPO?
What is the revenue of Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi (EGEPO)?
What is the net profit margin of EGEPO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.